跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
GLN-GABAPENTIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
GLN-GABAPENTIN
Authorized
STANDARD
GLN-GABAPENTIN
glenmark pharmaceuticals canada inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
bf9d3be7f36da21b
Company
glenmark pharmaceuticals canada inc.
Type
Standard
Approval Details
Approval Id
bf9d3be7f36da21b
Drug Approval Canada Name
GLN-GABAPENTIN
Product Name
GLN-GABAPENTIN
Status
Marketed
Status Date
2019-05-29
Original Market Date
2016-04-04
Din
02411008
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
28:12.92
Atc Original
N02BF01 GABAPENTIN
Atc Name
n 02 bf 01
Aig Number
0125929005
Company Name
glenmark pharmaceuticals canada inc.
Company Address
1600 Steeles Ave. W., Suite 407, Concord, Ontario, Canada, L4K 4M2
Active Ingredients
GABAPENTIN
800 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
bf9d3be7f36da21b
Type
Standard
Back to Health Canada Approvals